⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DWTX News
Dogwood Therapeutics, Inc. Common Stock
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
globenewswire.com
DWTX
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
globenewswire.com
DWTX
Form 8-K
sec.gov
DWTX
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
globenewswire.com
DWTX
Form 8-K
sec.gov
DWTX
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
globenewswire.com
DWTX
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
globenewswire.com
DWTX
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
globenewswire.com
DWTX
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
globenewswire.com
DWTX
Form 8-K
sec.gov
DWTX